ArticleVirchows Archiv : an international journal of pathology2017
Quality assurance trials for Ki67 assessment in pathology.
Article in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.Current oncology (Toronto, Ont.) · 2023Guideline
- Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature.Journal of endocrinological investigation · 2020Pooled it
- Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.Journal of neuropathology and experimental neurology · 2026Article
- High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial.Virchows Archiv : an international journal of pathology · 2025Article
- Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.Geburtshilfe und Frauenheilkunde · 2024Article
- Clinical validity and clinical utility of Ki67 in early breast cancer.Therapeutic advances in medical oncology · 2022Review
- Response to Zhang and Yang.Journal of the National Cancer Institute · 2021Article
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.Journal of the National Cancer Institute · 2021Article
- Ki67 expression at Kasai portoenterostomy as a prognostic factor in patients with biliary atresia.BJS open · 2020Article
- Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.Virchows Archiv : an international journal of pathology · 2020Article
- Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.Breast (Edinburgh, Scotland) · 2020Article
- Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients.Clinical epidemiology · 2020Article
- Recurrence/Regrowth in Grade I Meningioma: How to Predict?Frontiers in oncology · 2020Article
- Article
- Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Observational
- [Ki67: biological intertumor variance versus variance of assay].Der Pathologe · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ki67 is a broadly used proliferation marker in surgical pathology with an obvious need for standardization to improve reproducibility of assessment. Here, we present results of the so far only existing round robin tests on Ki67, organized annually in Germany, Austria, and Switzerland from 2010 to 2015 with up to 160 participating laboratories (QuIP). In each quality assessment trial, eight probes from each breast cancer, neuroendocrine tumor, and malignant lymphoma were compiled on a tissue microarray (TMA). TMAs were stained in the participants' laboratories with antibodies and procedures also applied in their daily routine. Participating pathologists were expected to assign Ki67 values to one of four different categories for each tumor type. All local stainings and evaluations were reassessed by the organizing panel and compared to a preset standard. On average, 95% of participants reached the benchmark of over 80% concordance rates with the Ki67 category pre-established by the panel. Automatization and type of antibody did not affect the success rate. Concordance rates differed between tumor entities being highest in each tumor type with either very high or very low labeling indices. Lower rates were seen for intermediate Ki67 levels. Staining quality improved during the observation period as did inter-observer concordance with 85% of participants achieving excellent agreement (kappa > 0.8) in the first year and over 95% in 2015. In conclusion, regular external quality assurance trials have been established as a tool to improve the reproducibility and reliability of the prognostic and predictive proliferation marker Ki67.
Indexed as
Identifiers
28497316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.